China Medical Technologies (CMED) Completes Development of Two Down Syndrome Diagnostic Reagents
China Medical Technologies (NASDAQ: CMED) has successfully completed the development of two Down syndrome diagnostic reagents that use chemiluminescence immunoassay technology. The Company is expected to introduce these two new reagents in early 2007, bringing the Company's total kit offering to 58 from 56.
The two new Down syndrome reagents are designed to measure the free beta subunit of human Chorionic Gonadotrophin and Pregnancy Associated Plasma Protein A, respectively, in maternal serum, which are important markers of Down syndrome.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
